Combining hippocampal volume metrics to better understand Alzheimer’s disease progression in at-risk individuals

To date nearly all clinical trials of Alzheimer’s disease (AD) therapies have failed. These failures are, at least in part, attributable to poor endpoint choice and to inadequate recruitment criteria. Recently, focus has shifted to targeting at-risk populations in the preclinical stages of AD thus i...

Descripción completa

Detalles Bibliográficos
Autores principales: McRae-McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., Anderson, R. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522521/
https://www.ncbi.nlm.nih.gov/pubmed/31097733
http://dx.doi.org/10.1038/s41598-019-42632-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522521/
https://www.ncbi.nlm.nih.gov/pubmed/31097733
http://dx.doi.org/10.1038/s41598-019-42632-w

Ejemplares similares